Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jan 20;42(3):324-335.
doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17.

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Affiliations
Clinical Trial

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Charles M Rudin et al. J Clin Oncol. .

Abstract

Purpose: The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung cancer (ES-SCLC). We report final progression-free survival (PFS) and overall survival (OS) analyses.

Methods: Patients received tiragolumab 600 mg/placebo, plus atezolizumab 1,200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab. Primary end points were investigator-assessed PFS and OS in patients without history/presence of brain metastases (primary analysis set [PAS]). Additional end points included PFS and OS in all patients regardless of brain metastases status (full analysis set [FAS]), response, and safety.

Results: Four hundred ninety patients were randomly assigned (FAS): 243 to tiragolumab arm and 247 to control arm. At the cutoff date (February 6, 2022; median duration of follow-up, 14.3 months [PAS] and 13.9 months [FAS]), final analysis of PFS in the PAS (n = 397) did not reach statistical significance (stratified hazard ratio [HR], 1.11; P = .3504; median, 5.4 months tiragolumab v 5.6 months control). At the cutoff date (September 6, 2022; median duration of follow-up, 21.2 months [FAS]), median OS in the PAS at final OS analysis was 13.1 months in both arms (stratified HR, 1.14; P = .2859). Median PFS and OS in the FAS were consistent with the PAS. The proportion of patients with immune-mediated adverse events (AEs) in the tiragolumab and control arms was 54.4% and 49.2%, respectively (grade 3/4: 7.9% and 7.7%). AEs leading to treatment withdrawal occurred in 8.4% and 9.3% of tiragolumab- and control-treated patients, respectively.

Conclusion: Tiragolumab did not provide additional benefit over atezolizumab and CE in untreated ES-SCLC. The combination was well tolerated with no new safety signals.

Trial registration: ClinicalTrials.gov NCT04256421.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Figures

FIG 1.
FIG 1.
CONSORT diagram. aIncludes two patients who screen-failed, rescreened, and later enrolled. bEntered in error. CE, carboplatin plus etoposide.
FIG 2.
FIG 2.
PFS in (A) the primary analysis set and (B) the full analysis set. Clinical cutoff date: February 6, 2022. CE, carboplatin plus etoposide; HR, hazard ratio; NE, not evaluable; PFS, progression-free survival. aStratification factors are Eastern Cooperative Oncology Group and lactate dehydrogenase. bStatistical boundary: 0.001.
FIG 3.
FIG 3.
OS in (A) the primary analysis set and (B) the full analysis set. Clinical cutoff date: September 6, 2022. CE, carboplatin plus etoposide; HR, hazard ratio; NE, not evaluable; OS, overall survival.
FIG 4.
FIG 4.
Overall survival in key patient subgroups in (A) PAS, (B) PAS BEP, (C) FAS, and (D) FAS BEP. Clinical cutoff date: September 6, 2022. BEP, biomarker-evaluable; CE, carboplatin plus etoposide; ECOG, Eastern Cooperative Oncology Group; eCRF, electronic case report form; FAS, full analysis set; HR, hazard ratio; IC, immune cell score; LDH, lactate dehydrogenase; NE, not evaluable; PAS, primary analysis set; TC, tumor cell; ULN, upper limit of normal.

Similar articles

Cited by

References

    1. Horn L, Mansfield AS, Szczęsna A, et al. : First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220-2229, 2018 - PubMed
    1. Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. 2022. http://NCCN.org
    1. Paz-Ares L, Dvorkin M, Chen Y, et al. : Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 394:1929-1939, 2019 - PubMed
    1. Cheng YC, Han L, Wu L, et al. : Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer. JAMA 328:1223-1232, 2022 - PMC - PubMed
    1. Liu SV, Reck M, Mansfield AS, et al. : Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 39:619-630, 2021 - PMC - PubMed

Publication types

MeSH terms

Associated data